Participant uptake of the fecal immunochemical test decreases with the two-sample regimen compared with one-sample FIT

European Journal of Cancer Prevention

Volumn 23, Issue 6, 2014, Pages 516-523

  Mosen, David M ^a   Liles, Elizabeth G ^a   Feldstein, Adrianne C ^a,b   Perrin, Nancy ^a   Rosales, Anna G ^a   Keast, Erin ^a   Smith, David H ^a  

^a CENTER FOR HEALTH RESEARCH   (United States)

^b KAISER PERMANENTE   (United States)

Author keywords

Colorectal cancer; Fecal immunochemical tests; Participant uptake

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CLINICAL EVALUATION; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FECAL IMMUNOCHEMICAL TEST; FECES ANALYSIS; FEMALE; FOLLOW UP; HUMAN; IMMUNOLOGICAL PROCEDURES; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; CHEMISTRY; COLORECTAL NEOPLASMS; DIAGNOSTIC KIT; EARLY DIAGNOSIS; FECES; IMMUNOHISTOCHEMISTRY; INFORMATION PROCESSING; MIDDLE AGED; PATIENT PARTICIPATION; POSTAL MAIL; PROCEDURES; STATISTICS AND NUMERICAL DATA; UTILIZATION;

DIAGNOSTIC KIT;

AGED; COLORECTAL NEOPLASMS; DATA COLLECTION; EARLY DETECTION OF CANCER; FECES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PATIENT PARTICIPATION; POSTAL SERVICE; REAGENT KITS, DIAGNOSTIC;

EID: 84914176081     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0000000000000084     Document Type: Article

References (45)

1. Atkin WS, Edwards R, Kralj-Hans I,Wooldrage K, Hart AR, Northover JM, et al. UK Flexible Sigmoidoscopy Trial Investigators (2010). Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 375:1624-1633.
2. Australian Government Department of Health and Aging (2013). National Bowel Cancer Screening Program.
3. Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987). A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373-383.
4. Cole SR, Young GP, Esterman A, Cadd B, Morcom J (2003). A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer . J Med Screen 10:117-122.
5. Cole SR, Tucker GR, Osborne JM, Byrne SE, Bampton PA, Fraser RJ, Young GP (2013). Shift to earlier stage at diagnosis as a consequence of the National Bowel Cancer Screening Program. Med J Aust 198:327-330.
6. De Wijkerslooth TR, Stoop EM, Bossuyt PM, Meijer GA, van Ballegooijen M, van Roon AH, et al. (2012). Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasi a. Am J Gastroenterol 107:1570-1578.
7. Denters MJ, Deutekom M, Fockens P, Bossuyt PM, Dekker E (2009). Implementation of population screening for colorectal cancer by repeated fecal occult blood test in the Netherlands. BMC Gastroenterol 9:28.
8. Deyo RA, Cherkin DC, Ciol MA (1992). Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45:613-619.
9. Digby J, McDonald PJ, Strachan JA, Libby G, Steele RJ, Fraser CG (2013). Use of a faecal immunochemical test narrows current gaps in uptake for sex, age and deprivation in a bowel cancer screening programme. J Med Screen 20:80-85.
10. Doubeni CA,Weinmann S, Adams K, Kamineni A, Buist DS, Ash AS, et al. (2013). Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study. Ann Intern Med 158:312-320.
11. Federici A, Giorgi Rossi P, Borgia P, Bartolozzi F, Farchi S, Gausticchi G (2005). The immunochemical faecal occult blood test l eads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial. J Med Screen 12:83-88.
12. Fenton JJ, Elmore JG, Buist DS, Reid RJ, Tancredi DJ, B aldwin LM (2010). Longitudinal adherence with fecal occult blood test screening in community practice. Ann Fam Med 8:397-401.
13. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Available at: http://globocan.iarc.fr.
14. Fraser CG, Allison JE, Halloran SP, Young GP. Expert Working Grou p on Fecal Immunochemical Tests for Hemoglobin, Colorectal Cancer Screening Committee,World Endoscopy Organization (2012). A proposal to standardize reporting units for fecal immunochemical tests for hemoglobin. J Natl Cancer Inst 104:810-814.
15. Gellad ZF,Stechuchak KM,Fisher DA,Olsen MK,McDuffie JR,Ostbye T,Yancy WS Jr. 2011 Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality Am J Gastroen terol 106 1125-1134.
16. Goede SL, van Roon AH, Reijerink JC, van Vuuren AJ, Lansdorp-Vogelaar I, Habbema JD, et al. (2013). Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. Gut 62:727-734.
17. Green BB, Wang CY, Anderson ML, Chubak J, Meenan RT, Vernon SW, Fuller S (2013). An automated intervention with stepped increases in support to incre ase uptake of colorectal cancer screening: a randomized trial. Ann Intern Med 158:301-311.
18. Hendren S, Winters P, Humiston S, Idris A, Li SX, Ford P, et al. (2014). Randomized, controlled trial o f a multimodal intervention to improve cancer screening rates in a safety-net primary care practice. J Gen Intern Med 29:41-49.
19. Hewitson P, Glasziou P,Watson E, Towler B, Irwig L (2008). Cochrane systematic review of colorectal cancer screening using the fecal occult blood test (Hemoccult): an update. Am J Gastroenterol 103:1541-1549.
20. Hoffman RM, Steel S, Yee EF, Massie L, Schrader RM, Murata GH (2010). Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial. Prev Med 50:297-299.
21. Hol L, Wilschut JA, van Ballegooijen M, van Vuuren AJ, van der Valk H, Reijerink JC, et al. (2009). Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at diffe rent cut-off levels. Br J Cancer 100:1103-1110.
22. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME. Colorectal Cancer Study Group (2004). Fecal DNA versus fecal occult blood for colorecta l-cancer screening in an average-risk population. N Engl J Med 351:2704-2714.
23. Kuntz J, Johnson E, Raebel M, Petrik A, Yang X, Thorp M, et al. (2012). Epidemiology and healthcare costs of inciden t Clostridium difficile infections identified in the outpatient healthcare setting. Infect Control Hosp Epidemiol 33:1031-1038.
24. Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, Caces ER (2005). Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 115:493-496.
25. Lee JK, Liles EG, Bent S, Levin TR, Corley DA (2014). Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med 160:171-181.
26. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. (2008). Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer S ociety, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 58:130-160.
27. Lieberman DA, Weiss DG. Veterans Affairs Cooperative Study Group 380 (2001). One-time screening for colorectal cancer with combined fecal occultblood testing and examination of the distal colon. N Engl J Med 345:555-560.
28. Lieberman DA,Weiss DG, Harford WV, Ahnen DJ, Provenzale D, Sontag SJ, et al. (2007). Five-year colon surveillance after screening colonoscopy. Gastroenterology 133:1077-1085.
29. Liles EG, Perrin N, Rosales AG, Feldstein AC, Smith DH, Mosen DM, Schneider J L (2012). Change to FIT increased CRC screening rates: evaluation of a US screening outreach program. Am J Manag Care 18:588-595.
30. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F (1993). Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 328:1365-1371.
31. Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y (2005). A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 129:422-428.
32. Mosen DM, Feldstein AC, Perrin N, Rosales AG, Smith DH, Liles EG, et al. (2010). Automated telephone calls improved completion of fecal occult blood testing. Med Care 48:604-610.
33. Myers RE, Sifri R, Hyslop T, Rosenthal M, Vernon SW, Cocroft J, et al. (2007). A randomized controlled trial of the impact of targeted and tailored interventions on colorectal cancer screening. Cancer 110 :2083-2091.
34. Myers RE, Hyslop T, Sifri R, Bittner-Fagan H, Katurakes NC, Cocroft J, et al. (2008). Tailored navigation in colorectal cancer screening. Med Care 46: S123-S131.
35. Mysliwiec P, Courteau S, Zhao W, Chung E, Maurer D, Levin T (2008). T1110, a colorectal cancer screening outreach using fecal immunochemical tests. Gastroenterology 134:A-485-A-486.
36. Nakama H, Yamamoto M, Kamijo N, Li T, Wei N, Fattah AS, Zhang B (1999). Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 46:228-231.
37. Nishihara R, Wu K, Lochhead P, Morikawa T, Liao X, Qian ZR, et al. (2013). Longterm colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med 369:1095-1105.
38. Parente F, Ma rino B, DeVecchi N, Moretti R, Ucci G, et al. Lecco Colorectal Cancer Screening Group (2009). Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cance r. Br J Surg 96:533-540.
39. Park DI, Ryu S, Kim YH, Lee SH, Lee CK, Eun CS, Han DS (2010). Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at av erage risk undergoing colorectal cancer screening. Am J Gastroenterol 105:2017-2025.
40. Riemann JF (2011). Colonoscopy screening: status in Europe. Dig Dis 29 (Suppl 1): 53-55.
41. Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, et al. (2009). Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal n eoplasms. Aliment Pharmacol Ther 29:450-457.
42. Van Rossum LG, van Rijn AF, Laheij RJ, van Oijen MG, Fockens P, van Krieken HH, et al. (2008). Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 135:82-90.
43. Von Karsa L, Patnick J, Segnan N, Atkin W, Halloran S, Lansdorp-Vogelaar I, et al. (2013). European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy 45:51-59.
44. Whitlock EP, Lin JS, Liles E, Beil TL, Fu R (2008). Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 149:638-658.
45. Zavoral M, Suchanek S, Zavada F, Dusek L, Muzik J, Seifert B, Fric P (2009). Colorectal cancer screening in Europe. World J Gastroenterol 15:5907-5915.